Overview

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This is a phase II, single arm, non-randomized, open label study of liposomal irinotecan with FOLFOX in the neoadjuvant setting in patients with resectable or borderline resectable, previously untreated pancreatic adenocarcinoma. The primary objective of this study is to investigate the safety and feasibility of this treatment regimen in this patient population.

Phase:

Phase 2

Details

Lead Sponsor:

University of Florida

Collaborator:

Ipsen

Treatments:

Camptothecin
Irinotecan
Oxaliplatin